## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

No clear thesis: MRS_10 at 3.3%, does not meet entry criteria. Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($192.07)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Morgan Stanley Highlights Positive Outlook for Becton, Dickinson (BDX) and the MedTech Sector**
- Source: Insider Monkey | 20251211T072005 | Bullish | Relevance: 99%
-  Morgan Stanley analyst Patrick Wood increased the price target for Becton, Dickinson and Company (BDX) to $210 from $197, maintaining an Overweight rating due to a positive outlook for the MedTech sector. The analyst cited major product cycles, healthier hospital spending, and low valuations as supporting factors for the industry. BDX reported strong fiscal Q4 2025 revenues of $5.9 billion, an 8.3% YoY growth, and plans to complete the merger of its Biosciences and Diagnostic Solutions (New BD) with Waters Corporation by Q1 2026.

**2. Morgan Stanley Highlights Positive Outlook for Becton, Dickinson (BDX) and the MedTech Sector**
- Source: Insider Monkey | 20251211T021300 | Bullish | Relevance: 99%
-  Morgan Stanley analyst Patrick Wood increased the price target for Becton, Dickinson and Company (NYSE: BDX) to $210 from $197, maintaining an "Overweight" rating, citing major product cycles, healthier hospital spending, and attractive valuations within the MedTech sector. Becton, Dickinson reported strong Q4 2025 revenues of $5.9 billion, an 8.3% YoY growth, and detailed the merger plans for its Biosciences and Diagnostic Solutions (New BD) with Waters Corporation. The company demonstrated commitment to shareholder value by returning $2.2 billion through dividends and share repurchases.

**3. Natixis Has $10.33 Million Position in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251209T130752 | Neutral | Relevance: 98%
- Natixis reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 42.9% in Q2, ending with 59,997 shares valued at $10.33 million. Despite this, institutional investors collectively own about 86.97% of the medical instruments supplier's stock. Becton, Dickinson recently increased its quarterly dividend to $1.05 per share, resulting in an annualized dividend of $4.20 and a yield of 2.2%.

**4. Jefferies Adjusts PT on Becton, Dickinson and Co. to $220 From $215, Maintains Buy Rating**
- Source: marketscreener.com | 20251210T140412 | Somewhat-Bullish | Relevance: 98%
-  Jefferies has updated its price target for Becton, Dickinson and Co. (BDX) to $220, an increase from its previous target of $215. The firm has also chosen to maintain its "Buy" rating for the medical technology company. This adjustment reflects Jefferies' continued positive outlook on Becton, Dickinson and Co.'s stock performance.

**5. Becton, Dickinson and Company $BDX Shares Sold by Ossiam**
- Source: MarketBeat | 20251209T123607 | Neutral | Relevance: 97%
- Ossiam reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 62.8% in Q2, selling 36,005 shares and retaining 21,357 shares valued at approximately $3.68 million. The company recently increased its quarterly dividend to $1.05 per share, payable on December 31st, implying a 2.2% yield. Analysts currently hold an average "Hold" rating on BDX with a price target of $204.45.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $210 | $197 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 13 ($0.04M) |
| Sells | 6 ($0.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +4.9% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.97 indicates undervaluation relative to growth. Balance sheet: $2.7B free cash flow. Analyst sentiment positive (1 raises, avg +7%). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $57.4B |
| Beta | 0.28 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.97 |
| Forward P/E | 12.6 |
| Current P/E | 13.4 |
| YoY Growth | 6.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.6% to 3.3% (+4.9% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 74th percentile. MRS_5 at 3.3% confirms short-term momentum alignment. Outperforming sector by 5.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.34% (CS: 74) | Strong |
| RSI_14 | 64.5 | Neutral |
| MACD Histogram | 0.43 | Bullish |
| vs SMA20 | 1.039x | Above |
| vs SMA50 | 1.062x | Above |
| vs SMA200 | 1.052x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $200.43
- **Stop Loss:** $192.07 (4.2% risk)
- **Target:** $208.79 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 165
- **Position Value:** $33,070.95
- **Portfolio %:** 33.07%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*